Ultrapure dialysate and inflammatory response in haemodialysis evaluated by darbepoetin requirements - A randomized study

Nephrology Dialysis Transplantation

Volumn 21, Issue 10, 2006, Pages 2851-2858

  Lamas, José M ^a   Alonso, Mario ^a   Sastre, Fernando ^b   García Trío, Gerardo ^a   Saavedra, Jesús ^a   Palomares, Luisa ^b  

^a UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^b Section of Nephrology   (Spain)

Author keywords

C reactive protein; Darbepoetin; Endotoxins; Haemodialysis; Haemoglobin; Inflammation; Interleukin; Ultrapure dialysate

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; POLYAMIDE;

ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSATE; DIALYSIS MEMBRANE; DRUG DOSE REGIMEN; FEMALE; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; INFECTION; INFLAMMATORY DISEASE; INTERMETHOD COMPARISON; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN DETERMINATION; RANDOMIZED CONTROLLED TRIAL; ULTRAFILTRATION;

AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; ERYTHROPOIETIN; FEMALE; FOLLOW-UP STUDIES; HEMATINICS; HEMODIALYSIS SOLUTIONS; HEMOGLOBINS; HUMANS; INFLAMMATION; INTERLEUKIN-6; KIDNEY; MALE; MIDDLE AGED; RENAL DIALYSIS; SERUM ALBUMIN; TIME FACTORS;

EID: 33749641706     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl322     Document Type: Article

References (27)

1. Yao Q, Axelsson J, Stenvinkel P, Lindholm B. Chronic systemic inflammation in dialysis patients: An update on causes and consequences. ASAIO J 2004; 50: 52-57
2. Kaysen G. Serum albumin concentration in dialysis patients: Why does it remain resistant to therapy? Kidney Int 2003; 64 [Suppl 87]: S92-S98
3. Drüecke T. β2-microglobulin and amyloidosis. Nephrol Dial Transplant 2000; 15 [Suppl 1]: 17-24
4. Goicoechea M, Martin J, Sequera P et al. Role of cytokines in the response to erythropoietin in haemodialysis patients. Kidney Int 2000; 54: 1337-1343
5. Bologa R, Levine D, Parker T et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia and mortality in haemodialysis patients. Am J Kidney Dis 1998; 32: 107-114
6. Pereira B. Balance between pro-inflammatory cytokines and their specific inhibitors in patients on dialysis. Nephrol Dial Transplant 1995; 10 [Suppl 7]: 27-32
7. Dinarello C. Interleukin-1 and Interleukin-1 receptor antagonist production during haemodialysis: Which cytokine is a surrogate marker for dialysis-related complications? Nephrol Dial Transplant 1995; 10 [Suppl 3]: 25-28
8. Lonneman G. The quality of dialysate: An integrated approach. Kidney Int 2000; 58 [Suppl 76]: S112-S119
9. Schindler R, Lonnemann G, Schäffer J, Shaldon S, Koch K, Krautzig S. The effect of ultrafiltered dialysate on the cellular content of interleukin-1 receptor antagonist in patients on chronic haemodialysis. Nephron 1994; 68: 229-233
10. Sitter T, Bergner A, Schiffl H. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. Nephrol Dial Transplant 2000; 15: 1207-1211
11. Schiffl H, Lang S, Bergner A. Ultrapure dialysate reduces dose of recombinant human erythropoietin. Nephron 1999; 83: 278-279
12. Schiffl H, Lang S, Stratakis D, Fischer R. Effects of ultrapure dialysis fluid on nutritional status and inflammatory parameters. Nephrol Dial Transplant 2001; 16: 1863-1869
13. Schiffl H, Lang S, Fischer R. Ultrapure dialysis fluid slows loss of an residual renal function in new dialysis patients. Nephrol Dial Transplant 2002; 17: 1814-1818
14. Kleophas W, Haastert B, Backus G, Hilgers P, Westhoff A, Endert G. Long-term experience with an ultrapure individual dialysis fluid with a batch type machine. Nephrol Dial Transplant 1998; 13: 3118-3125
15. Ledebo I, Nystrand R. Defining the microbiological quality of dialysis fluid. Artif Organs 1999; 23: 37-43
16. Baz M, Durand C, Ragon A et al. Using ultrapure water in haemodialysis delays carpal tunnel syndrome. Int J Artif Organs 1991; 14: 681-685
17. Comité técnico Aenor. Norma UNE 111-301-90. Características del agua utilizada en hemodiálisis. Nefrología 1991; 11: 7-8
18. Schwalbe S, Holzhauer M, Schaeffer J, Galanski M, Koch K, Floege J. β2-microglobulin associated amyloidosis: A vanishing complication of long-term haemodialysis. Kidney Int 1997; 52: 1077-1083
19. Bommer C, Bommer J, Ritz E. Do we need ultrapure dialysate for haemodialysis in general? ASN Annual Meeting - St Louis. J Am Soc Nephrol 2004; 14: 166A
20. Yamagami S, Adachi T, Sugimura T et a. Detection of endotoxin antibody in long-term dialysis patients. Int J Artif Organs 1990; 13: 205-210
21. Bommer J, Becker K, Urbaschek R. Potential transfer of endotoxin across high-flux polysulfone membranes. J Am Soc Nephrol 1996; 7: 883-888
22. Vanholder R, Van Haeche E, Veys N, Ringoir S. Endotoxin transfer through dialysis membranes: Small versus large pore membranes. Nephrol Dial Transplant 1992; 7: 333-339
23. Nubé M, Grooteman M. Impact of contaminated dialysate on long-term haemodialysis-related complications: Is it really that important? Nephrol Dial Transplant 2001; 16: 1986-1991
24. Ertl T, Beck W, Schnell A et al. Barrier function of low and high flux synthetic membranes for endotoxins in contaminated dialysis fluid. Blood urif 2003; 21: 35
25. Pereira B, Sundaram, S, Barrett T et al. Transfer of cytokine-inducing bacterial products across haemodialyser membranes in the presence of plasma or whole blood. Clin Nephrol 1996; 46: 394-401
26. Bambauer R, Schauer M, Jung W, Vienken J. Contamination of dialysis water and dialysate. A survey of 30 centers. ASAIO J 1994; 40: 1012-1016
27. Tielemans C. Are standards for dialysate purity in haemodialysis insufficiently strict? Semin Dial 2001; 14: 328-329